While Aclaris Therapeutics Inc has underperformed by -9.16%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ACRS rose by 131.78%, with highs and lows ranging from $5.17 to $0.86, whereas the simple moving average jumped by 54.46% in the last 200 days.
On December 23, 2024, H.C. Wainwright Upgraded Aclaris Therapeutics Inc (NASDAQ: ACRS) to Buy. A report published by Cantor Fitzgerald on November 20, 2024, Upgraded its rating to ‘Overweight’ for ACRS. Leerink Partners also Upgraded ACRS shares as ‘Outperform’, setting a target price of $7 on the company’s shares in a report dated November 19, 2024. Jefferies November 19, 2024d the rating to Buy on November 19, 2024, and set its price target from $2 to $7. BTIG Research November 19, 2024d its ‘Neutral’ rating to ‘Buy’ for ACRS, as published in its report on November 19, 2024. Piper Sandler’s report from November 18, 2024 suggests a price prediction of $13 for ACRS shares, giving the stock a ‘Overweight’ rating. H.C. Wainwright also rated the stock as ‘Neutral’.
Analysis of Aclaris Therapeutics Inc (ACRS)
Further, the quarter-over-quarter decrease in sales is -53.18%, showing a negative trend in the upcoming months.
Aclaris Therapeutics Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -25.83% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 7.03, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and ACRS has an average volume of 2.40M. On a monthly basis, the volatility of the stock is set at 8.81%, whereas on a weekly basis, it is put at 8.46%, with a loss of -8.82% over the past seven days. Furthermore, long-term investors anticipate a median target price of $10.00, showing growth from the present price of $2.48, which can serve as yet another indication of whether ACRS is worth investing in or should be passed over.
How Do You Analyze Aclaris Therapeutics Inc Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 16.13%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 75.64% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
ACRS shares are owned by institutional investors to the tune of 75.64% at present.
